164 related articles for article (PubMed ID: 37067794)
1. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
2. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
[TBL] [Abstract][Full Text] [Related]
3. Drugs likely subject to Medicare negotiation, 2026-2028.
Dickson S; Hernandez I
J Manag Care Spec Pharm; 2023 Mar; 29(3):229-235. PubMed ID: 36840960
[No Abstract] [Full Text] [Related]
4. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
5. Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016-2019 data.
Qureshi O; Ramachandran R; Ross JS
J Pharm Policy Pract; 2024; 17(1):2312374. PubMed ID: 38434725
[TBL] [Abstract][Full Text] [Related]
6. Estimated discounts generated by Medicare drug negotiation in 2026.
Hernandez I; Gabriel N; Dickson S
J Manag Care Spec Pharm; 2023 Aug; 29(8):868-872. PubMed ID: 37523318
[No Abstract] [Full Text] [Related]
7. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
8. The Inflation Reduction Act: A boon for the generic and biosimilar industry.
Niazi SK
J Clin Pharm Ther; 2022 Nov; 47(11):1738-1751. PubMed ID: 36207987
[TBL] [Abstract][Full Text] [Related]
9. Why Does the Inflation Reduction Act Exclude Expensive Cancer Treatments in Price Negotiations?
Horn DM; Jacobson M; Alpert AE; Duggan MG
JCO Oncol Pract; 2024 Feb; 20(2):254-261. PubMed ID: 38060993
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
Sumarsono A; Sumarsono N; Das SR; Vaduganathan M; Agrawal D; Pandey A
JAMA Netw Open; 2020 Feb; 3(2):e200181. PubMed ID: 32108893
[TBL] [Abstract][Full Text] [Related]
11. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
12. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
13. Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.
Vogel M; Zhao O; Feldman WB; Chandra A; Kesselheim AS; Rome BN
JAMA Intern Med; 2024 Jan; 184(1):63-69. PubMed ID: 38010643
[TBL] [Abstract][Full Text] [Related]
14. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
15. Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act.
Vogel M; Kakani P; Chandra A; Conti RM
Nat Biotechnol; 2024 Mar; 42(3):406-412. PubMed ID: 38297186
[TBL] [Abstract][Full Text] [Related]
16. The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease?
Johnson M; Kishore S; Nayak RK; Dusetzina SB
Curr Cardiol Rep; 2023 Jun; 25(6):577-581. PubMed ID: 37097432
[TBL] [Abstract][Full Text] [Related]
17. Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study.
Liu M; MacKenna B; Feldman WB; Walker AJ; Avorn J; Kesselheim AS; Goldacre B
J R Soc Med; 2020 Sep; 113(9):350-359. PubMed ID: 32910868
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
19. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
20. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
